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96 The Journal of Thoracic and Cardiobjective: Oxidative stress and systemic inflammation response contribute to acute
enal injury post cardiac surgery. We hypothesized that administration of the
ntioxidant N-acetylcysteine would be beneficial to renal function after cardiopul-
onary bypass in a rat model.
ethods: Male Sprague–Dawley rats were divided into four groups (each n  6):
ham group, cardiopulmonary bypass group, and two N-acetylcysteine–treated
ardiopulmonary bypass groups (bolus doses of 200 and 500 mg/kg in cardiopul-
onary bypass prime). Blood samples were collected at the beginning of cardio-
ulmonary bypass, at the cessation of cardiopulmonary bypass, and at 2 and 12
ostoperative hours. The kidneys were harvested at 12 postoperative hours.
esults: Serum creatinine and cystatin C continuously increased in all cardiopul-
onary bypass groups (P .05 within groups). Tubular dilatation, tubular necrosis,
nd vacuole formation were found in epithelial cells in histomorphologic studies of
he cardiopulmonary bypass groups, but N-acetylcysteine significantly reversed
hese effects (P .05 between groups). Compared with the sham group, the reduced
lutathione hormone content and the superoxide dismutase and catalase activities
ecreased in the cardiopulmonary bypass groups (P  .01). N-acetylcysteine–
reated groups had higher levels of these antioxidants than the untreated bypass
roup (P  .05). Renal malondialdehyde, tumor necrosis factor , and nuclear
actor B were notably increased in all cardiopulmonary bypass groups relative to
he sham group (P  .01), and N-acetylcysteine attenuated these changes dose
ependently.
onclusion: Administration of the antioxidant N-acetylcysteine preserved renal
unction after cardiopulmonary bypass dose dependently. Furthermore, oxidative
tress and systemic inflammation were significantly reduced in the treated animals.
cute renal dysfunction affects about 5% to 31% of patients who undergo
cardiac surgery with cardiopulmonary bypass (CPB), and it is associated
with mortality.1 Potential reasons for renal dysfunction include cardiovas-
ular compromise, prolonged CPB exposure, increased catecholamine level, non-
ulsatile flow, hypothermia, renal hypoperfusion, and the induction of inflammatory
ediators.2 These factors may collectively contribute to renal hypoxic-ischemic and
ystemic inflammatory responses. These insults result in generous formation of
eactive oxygen species and depletion of endogenous antioxidants.
A number of possible strategies aimed at alleviating the development of renal
ysfunction have been evaluated. Although commonly used approaches to prevent
cute renal failure have included adequate hydration, mannitol, renal doses of
opamine, and loop diuretics, examination of the evidence does not support the
ontinued use of all these regimens.3 Recently, several meta-analyses and random-
zed, controlled trials have demonstrated that N-acetylcysteine (NAC) attenuates
ontrast-associated declines in renal function, but the conclusion is still inconsis-
vascular Surgery ● March 2007
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Pent.4,5 NAC also attenuates kidney ischemia-reperfusion
njury.6 These protective effects may arise because NAC is
recursor of glutathione and scavenger of reactive oxygen
pecies. NAC has also been used to ameliorate inflamma-
ory response in lipopolysaccharide-induced acute lung in-
ury in rats and in an acute pancreatitis experimental
odel.7,8
Because NAC can ameliorate ischemia-reperfusion in-
ury and inflammatory response, which are the main patho-
hysiologic changes seen with CPB, it should be protective
n patients undergoing CPB.2,9-15 Several studies have
hown its myocardial protective effect in bypass surgery,
ut research concerning its renal protective effect is limited,
nd the results seem controversial.2,11 There are several
ossible reasons why a treatment effect was not ob-
erved, with two being most important. First, serum
reatinine is not a prompt marker of acute renal injury,
nd these studies lacked morphologic studies of renal
issue because of the clinical limitations. Second, the
ose of NAC, although well studied for prevention of
ontrast-induced nephropathy, may be inadequate to
ounteract the hypoxic-ischemic insults to the renal tu-
ular epithelial cells induced by CPB.2 In this study we
herefore aimed to determine the biochemical and mor-
hologic renal effects of NAC at different doses in a rat
odel of CPB and to investigate the potential mechanism
f this agent.
aterials and Methods
nimals and Groups
ale Sprague–Dawley rats (450-550 g) were used for the exper-
ment. All animals received humane care in compliance with “The
rinciples of Laboratory Animal Care” formulated by the National
ociety of Medical Research and with the “Guide for the Care
nd Use of Laboratory Animals” (http://www.nap.edu/catalog/
140.html). The following experimental protocol was approved by
ocal ethical committee.
Rats were randomly assigned to one of four groups (n  6 for
ach group): sham, CPB only (control), CPB plus low-dose (200
g/kg) NAC (low NAC), and CPB plus high-dose (500 mg/kg)
AC (high NAC). NAC or placebo was added into the prime
Abbreviations and Acronyms
CPB  cardiopulmonary bypass
GSH  reduced glutathione
MDA malondialdehyde
NAC  N-acetylcysteine
NF-B  nuclear factor B
SOD  superoxide dismutase
TNF   tumor necrosis factor f CPB. n
The Journal of Thoracicurgical Procedure
he rat model of CPB was built according to Dong and col-
eagues,16 and we performed some modifications that made our
odel very similar to the one used by Modine and associates.17
ats were anesthetized with intraperitoneal administration of
utaylone (60 mg/kg) at the beginning; additional pentobarbital
as added to ensure an adequate depth of anesthesia, and the
ncisions were infiltrated with 2% lidocaine intermittently. The
ight femoral artery was cannulated with a 24-gauge polytetrafluo-
oethylene heparinized catheter to monitor arterial pressure and to
ollect blood samples. After administration of heparin (250 U/kg),
16-gauge catheter, modified to a multiside-orifices cannula in the
orepart, was inserted into the right jugular vein and advanced to
he right atrium. A 22-gauge catheter was cannulated to the tail
rtery to serve as the arterial infusion line. Any rats that died
uring the institution of CPB were excluded.
The mini-CPB circuit comprised a venous reservoir, a specially
esigned membrane oxygenator, a roller pump, and sterile poly-
inyl chloride tubing with an internal diameter of 3 mm for the
enous and arterial lines (30 cm long; Figure E1. The roller pump
as equipped with a silicone tube 15 cm in length with an internal
iameter of 5 mm. The membrane oxygenator was specially de-
igned with a surface area for gas exchange of 0.05 m2 (Micro-1;
ewei Medical Instrument Inc, Dongguan, China), with its total
ssembly dynamic priming volume approximating 2 mL. Body
entral temperature was monitored with a rectal probe and kept at
6.5°C to 38.3°C by a heat lamp placed around the animal and the
PB equipment. We primed the CPB circuit with 12 mL of a
olution of heparin (250 U/kg), hetastarch, and NAC or placebo.
efore the initiation of extracorporeal circulation, the CPB set was
xamined carefully to avoid liquid and air leaks. The blood was
rained from the right atrium through the jugular vein catheter to
5-mL sterile open reservoir by gravity and siphon. A roller pump
BT00-300M; Lange Co, Baoding, China) was used to drive the
lood through silicone arterial inflow tubing and then return it to
he tail artery.
At the initiation of perfusion, the flow rate was gradually
ncreased to 100 mL/(kg · min) and maintained for 60 minutes; it
as then turned down step by step to maintain hemodynamic
tability. When the rat was weaned from CPB, the tail artery
atheter was removed, and the right jugular vein catheter was
rawn back to superior vena. The remaining priming solution was
nfused gradually when the main arterial pressure was less than 60
m Hg. After 1 hour of intensive postoperative care, the right
ugular vein catheter and the femoral artery catheter were decan-
ulated. Then the neck, tail, and groin incisions were sutured.
hroughout the experiment, the mean arterial pressure was main-
ained about 60 to 80 mm Hg. The rats were given water and food
hours after the operation, and they were monitored for 12
ostoperative hours.
pecimen Collection
ean arterial pressures were recorded during the experiment.
lood samples (1 mL) were obtained from the femoral artery
mmediately after heparinization, at the end of CPB, and at 2 and
2 hours after operation. These were used for blood gas analyses
nd later determinations of serum creatinine, cystatin C, and tumor
ecrosis factor  (TNF-). The urinary output in the first 2 hours
and Cardiovascular Surgery ● Volume 133, Number 3 697
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CSPas also collected. At 12 hours after the operation, the kidneys
ere harvested for microscopic examination and biochemical
nalysis.
iochemical Analysis of Renal Function
erum creatinine was measured with a kinetic Jaffe method mod-
fied to reduce the effect of noncreatinine Jaffe-reacting chromo-
ens. Serum cystatin C was measured by particle-enhanced neph-
lometric immunoassay (Beijing Strong Biotechnologies Inc,
eijing, China). Both were assayed on a chemistry analyzer
model 7600-020; Hitachi, Ltd, Tokyo, Japan).
ssays of Oxidative Stress Markers
he homogenate samples were prepared as described elsewhere.6
rotein measurements were analyzed according to the method of
owry and colleagues.18 Total (copper-zinc and manganese) su-
eroxide dismutase (SOD) activity was determined by the method
f Sun and coworkers19; SOD activities were expressed as unit per
illigram of protein. Catalase activity was determined according
o the method of Aebi20 and expressed as katals* per gram of
rotein. Tissue reduced glutathione (GSH) levels were measured
 y the method of Ellman21; values were expressed as nanomoles per
illigram of protein. The level of malondialdehyde (MDA) in tissue
omogenate was determined according to the method of Uchiyama
nd Mihara22 and expressed as nanomoles per gram of wet tissue.
etermination of Inflammation Markers
NF- concentrations in serum and renal tissues were quantified
ith enzyme-linked immunosorbent assay kits specific for the rat
ytokines according to manufacturer instructions (Tepnel Life-
odes Corp, Stamford, Conn, for TNF-). Values were expressed
s picograms per milliliter for serum and picograms per milligram
f protein for tissue samples.
The nuclear extracts were prepared as described elsewhere.23
lectrophoretic mobility shift assay was performed with a com-
ercial kit (Gel Shift Assay System; Promega Corporation,
adison, Wis). Nuclear factor B (NF-B) consensus oligonu-
leotide (AGT-TGA-GGG-GAC-TTT-CCC-AGG) was labeled
ith [-32P] adenosine triphosphate (Free Biotech, Beijing, China)
ith T4 polynucleotide kinase. Equal amounts of nuclear extract (60
g) were added to 9 L of gel shift binding buffer (10-mmol/L
ris(hydroxymethyl)aminomethane hydrochloride, pH 7.5, 50-mmol/
sodium chloride, 0.5-mmol/L ethylenediaminetetraacetic acid,
-mmol/L magnesium chloride, 0.5-mmol/L deoxythymidine triphos-
hate, 4% glycerol, 0.05-mg/mL polynucleotide deoxyinosine deoxy-
ytosine) for 15 minutes at room temperature. The mixture was
ncubated for 30 minutes with 1 L of the phosphorus 32–labeled
ligonucleotide probe. A 1-L portion of loading buffer was added,
nd the sample was electrophoresed in a 4% polyacrylamide gel at
90 V for 1 hour. The dried gel was exposed to x-ray film (Fuji
yperfilm; Fuji Photo Film Co, Ltd, Tokyo, Japan) at 70°C. The
ntensity of the NF-B complex was quantified by densitometry.
ight Microscopy
or microscopic evaluation, formalin-fixed kidney samples were
mbedded in paraffin, and 4-m sections were prepared. TheC
One katal represents the enzyme activity able to cleave 1 mol substrate per
econd.
98 The Journal of Thoracic and Cardiovascular Surgery ● Marcections were then stained with hematoxylin and eosin and scored
ccording to a previously described semiquantitative scale de-
igned to evaluate the degree of renal damage (tubular cell necro-
is, cytoplasmic vacuole formation, hemorrhage, and tubular dila-
ation6) by an investigator (HS) who was blinded to the grouping.
tatistical Analysis
ll values were expressed as mean SD. Data were analyzed with
commercially available statistical software package (SPSS for
indows version 13.0; SPSS Inc, Chicago, Ill). Either 1- or 2-way
nalysis of variance was used for comparisons between the groups
here appropriate, and we examined the time courses of each
easured parameter with repeated measures analysis of variance.
ost hoc comparisons were performed with the Tukey test or
unnett T3 test.
esults
erioperative Physiologic Data
ll the rats survived the CPB process, and their physiologic
ata before and after operation are summarized in Table 1.
he preoperative data were similar for all the four groups
nd did not change postoperatively in the sham group. In all
roups with CPB, mean arterial pressure decreased signifi-
antly from baseline to about 70 mm Hg (P  .001); PaO2
nd PaCO2 were both in our acceptable range; pH levels
eclined, indicating a tendency toward metabolic acidosis;
nd hematocrit significantly decreased from the hemodilu-
ion of CPB. Urinary volume increased in all CPB groups in
he first 2 hours from the beginning of operation, and
igh-dose NAC significantly increased urinary output (P 
018). No rats died during 12 postoperative hours.
ime Courses of Renal Markers
he changes of the renal markers, containing serum creat-
nine and cystatin C, are depicted in Figure 1. Serum cre-
tinine (Figure 1, A) was stable in the sham group through-
ut the experiment, whereas it continued increasing and was
ignificant higher than the baseline in all three CPB groups
P  .001, P  .001, and P  .002, for control, low NAC,
nd high NAC, respectively). Compared with the sham
roup, serum creatinine increased significantly in the con-
rol and low-NAC groups (P  .001 and 0.005, respec-
ively). NAC treatment significantly reduced the CPB-
nduced serum elevation relative to the control group (P 
02 and P  .001 for low NAC and high NAC, respec-
ively); however, no significant difference was found be-
ween the two NAC treatment groups (P  .348).
Serum cystatin C showed a similar pattern to that of
reatinine (Figure 1, B). Serum cystatin C rose gradually
n the sham group after the operation, but it did not
pproach statistical significance; in contrast, cystatin C
ignificantly increased postoperatively in the control
roup (P  .001), the low-NAC group (P  .001), and
he high-NAC group (P  .002) relative to baseline.
ystatin C increased remarkably in all CPB groups (P 
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P001, P  .002, and P  .081 for control, low NAC, and
igh NAC, respectively, vs sham). Relative to the control
roup, the administration of high-dose NAC significantly
nhibited the elevation of cystatin C (P  .03); however,
here were no significant differences between the two
AC treatment groups (P  .310).
ight Microscopic Examination Results
istologic damage ranged from normal (sham group) to
ild (NAC groups) and severe (CPB-only control group).
istologic changes, including tubular dilatation, tubular
ecrosis, and vacuole formation, were clearly observed in
he kidneys of all CPB groups (Figure 2, B-D). Cortical
ubular dilatation and vacuole formation were observed
o some extent in all groups except the sham group
Figure 2, A ). The control pathologic damage score after
PB-induced injury (3.3  0.5) was significantly re-
uced in the high-dose NAC group (2.0  0.6, P  .01),
hereas no difference was found between the control and
ow-dose NAC groups (2.7  0.6, P  .157). In the
igh-dose NAC group, generalized hemorrhage could be
bserved (Figure 2, D ).
ffects of NAC on Oxidative Stress Markers
he effects of NAC on renal MDA and GSH contents and
n SOD and catalase activities are shown in Table 2. The
evel of MDA significantly increased in control and low-
AC groups (P  .001 and P  .013, respectively) relative
o the sham group, and treatment with high-dose NAC
ignificantly reduced the CPB-enhanced MDA level (P 
001) relative to the control group. In the cases of the control
nd low-NAC groups, there were significant decreases (P
001 and P  .004, respectively) in GSH content relative to
he sham group. High-dose NAC treatment protected
ABLE 1. Physiologic data of the rats during experiments
Mean arterial
pressure (mm Hg) pH
ham
Preoperative 108.5 8.6 7.39 0.02
Postoperative 106.5 5.2 7.39 0.01
PB (control)
Preoperative 112 6.9 7.40 0.01
Postoperative 76 4.9*† 7.36 0.01*†
PB plus low-dose NAC
Preoperative 105.5 11 7.38 0.01
Postoperative 75.2 5.5*† 7.36 0.01*†
PB plus high-dose NAC
Preoperative 108.3 7.9 7.39 0.02
Postoperative 70.7 5.6*† 7.36 0.02*†
alues are means SD, n 6. CPB, Cardiopulmonary bypass; NAC, N-ace
rom sham group. ‡P  .01 for difference from control group.gainst CPB-induced reduction in GSH levels, as evidenced h
The Journal of Thoracicy a significant increase in GSH content relative to the
ontrol (P  .001) and low-NAC (P  .006) groups. The
ctivities of SOD and catalase were decreased significantly
n the control group relative to the sham group (P  .001).
hen compared with the control group, however, low-dose
AC supplementation significantly increased the SOD ac-
ivity (P  .003), whereas high-dose NAC treatment in-
reased the activities of both SOD and catalase significantly
P  .001).
ffects of NAC on Serum TNF-
he time course of serum TNF- concentration is depicted
n Figure 3. The levels of TNF- increased remarkably
ostoperatively. The difference with time (immediately af-
er heparinization, at the end of CPB, at 2 and 12 hours after
peration) within groups was statistically significant (P 
01), and strongly significant differences were found in each
omparison of two groups (P  .01).
ffects of NAC on Renal TNF- and NF-B
NF- levels in the kidney tissues significantly increased in
ll CPB groups relative to the sham group (1.39  0.31
g/mg protein). Relative to the control group (5.71  1.33
g/mg protein), NAC significantly depressed TNF- eleva-
ion (4.27  0.57 pg/mg protein, P  .01), and high-dose
AC showed more apparent effect (3.09  0.40 pg/mg
rotein, P  .013). The tendency of optical densities of
enal NF-B was similar with that of renal TNF-. Relative
o the sham group (1.18  0.06 times background), CPB
aused significant increased expression of NF-kappa B
2.42  0.19, P  .001), whereas NAC treatment amelio-
ated this effect (1.89 0.13 and 1.62 0.10, P .002 and
 .001 for low NAC and high NAC, respectively, vs
ontrol), and a more significant effect was found in the
PaO2 (mm Hg) PaCO2 (mm Hg) Hematocrit
Urine volume
first 2 h
162 17.5 39 2.4 46 3.2 1.9  0.6
64.7 14.2 39.5 1.5 44.5 2.1
60.5 13.9 38.3 2.6 46.5 2.4 2.25  0.7
51.7 33.6*† 40.8 3.1 30.8 1.7
56.8 10.8 41.2 3.7 44.8 2.8 3.2 1.1
1.33 27.5*† 39.3 2.2 28.8 1.2
60.5 11.9 39.3 3.0 46.0 2.8 4.3 1.5†‡
65.7 30.2*† 38.0 2.8 30.5 1.9
teine. *P .01 for difference from baseline period. †P .01 for difference1
1
3
1
35
1
3
tylcysigh-NAC group (P  .015 vs low NAC).
and Cardiovascular Surgery ● Volume 133, Number 3 699
D
O
i
w
r
b
p
o
k
h
N
e
l
p
s
u
r
a
d
b
m
v
e
e
c
s
m
t
a
F
c
b
c
p
i
P
F
e
g
e
I
g
t
Cardiopulmonary Support and Physiology Zhu et al
7
CSPiscussion
ur data show that NAC prevents CPB-induced acute renal
njury. Oxidative stress and systemic inflammation response
igure 1. Perioperative time courses of serum creatinine (A) and
ystatin C (B). NAC, N-acetylcysteine; T0, before cardiopulmonary
ypass; T1, at end of cardiopulmonary bypass; T2, 2 hours after
ardiopulmonary bypass; T3, 12 hours after cardiopulmonary by-
ass. Asterisk indicates P < .05 versus baseline; crosshatch
ndicates P < .05 versus sham group; ampersand indicates
< .05 versus control group.ere significantly lower in rats receiving NAC than in those d
00 The Journal of Thoracic and Cardiovascular Surgery ● Marceceiving placebo, and a higher dose of NAC displayed
etter protective effects.
There have been many studies focusing on the renal
rotective effects of NAC. Most, however, have been based
n renal ischemia-reperfusion models or toxic drug-induced
idney injury or acute inflammation models. Recently, there
ave been a few clinical trials concentrating on the effect of
AC in patients undergoing CPB, and their results are
ncouraging. Perioperative use of NAC showed cardiac and
ung protective effects,10,12,14,15,24 but its renal effect in
atients undergoing CPB seems inconsistent. Fish and as-
ociates11 reported renal protection by NAC in patients
ndergoing coronary artery bypass grafting, but another
andomized, controlled trial concluded that perioperative
dministration of NAC did not prevent postoperative renal
ysfunction in high-risk patients undergoing coronary artery
ypass grafting.2 Although such clinical trials give us the
ost direct evaluation of NAC treatment, they cannot pro-
ide us with morphologic data on renal tissues because of
thics restrictions, and there are some uncontrolled influ-
ncing factors. Additionally, the dose of NAC used in
linical trials seems a little conservative.
As far as we knew, until now there has been only one
tudy focusing on the effects of NAC in an animal CPB
odel.13 The authors used dogs in their experiment, and
hey concluded that NAC reduces lung reperfusion injury
fter deep hypothermia and total circulatory arrest. Nowa-
igure 2. Photomicrographs of renal cortical tubules (hematoxylin-
osin, 600) from each group. Tubules appear normal in sham
roup (A), whereas they appear dilated and lined by flattened
pithelial cells (some representing necrosis) in control group (B).
n low–N-acetylcysteine group (C) and high–N-acetylcysteine
roup (D), tubules are dilated slightly, and cytoplasm of some
ubular epithelial cells are filled with fine vacuoles.ays, most researchers use large animals to establish a CPB
h 2007
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Podel, because their anatomy and physiology are more
imilar to human beings. Large animal models, however, are
ncreasingly expensive, require sophisticated surgical ex-
ertise, and require much more time and labor, whereas a rat
odel is more convenient and cost-effective.16,17
We used a model designed by our colleagues in a pre-
ious study16; however, we made some modifications. First,
e used the tail artery for our arterial line, instead of the
ight carotid artery. In our preliminary experiment, we
ound that when we used the tail artery, the arterial pressure
as almost nonpulsatile during the extracorporeal circula-
ion period. This was closer to the clinical situation. Second,
e reduced the total prime volume to approximately 12 mL,
nd we did not add allogeneic blood to the prime. The
ematocrit was in our ideal range and did not result in
verhemodilution. Third, we kept the rats spontaneously
reathing instead of using tracheal intubation. Our experi-
ent achieved acceptable blood gas analysis results, which
uggests that the membrane oxygenation and oxygen inha-
ation together were enough to satisfy the requirements of
he rats. Finally, several drug doses in our experiment were
ABLE 2. Effects of N-acetylcysteine on malondialdehyde,
roup
Malondialdehyde
(nmol/g wet tissue)
Reduc
(nmo
ham 1.55 0.21 11.
ontrol 2.36 0.23* 6.
ow N-acetylcysteine 2.03 0.30† 7.
igh N-acetylcysteine 1.74 0.21‡ 11.
alues are mean  SD, n  6. *P  .01 for difference from sham group.
roup. §P  .05 for difference from low–N-acetylcysteine group. 2P  .0
igure 3. Effect of N-acetylcysteine (NAC) on serum TNF- level.
0, Before cardiopulmonary bypass; T1, at end of cardiopulmo-
ary bypass; T2, 2 hours after cardiopulmonary bypass; T3, 12
ours after cardiopulmonary bypass. Serum TNF- was elevated
ignificantly at end of cardiopulmonary bypass and continued to
ncrease. Significant differences were found within and betweenrroups.
The Journal of Thoracichanged because of the results of our preliminary
xperiment.
There are a number of available renal function tests.
erum creatinine has been the most widely used marker in
he last 40 years; however, its limitations are well known. It
ften overestimates glomerular filtration rate, it misses
ome subclinical kidney dysfunction, and its change falls
ehind glomerular filtration rate. Cystatin C, another glo-
erular filtration rate marker, has been well studied in the
ast two decades. The available data have indicated that
erum cystatin C is superior to serum creatinine in various
elected cases.25 Recent research indicates that cystatin C is
reliable renal marker for patients undergoing on-pump
oronary artery bypass grafting,26 and it was proved in
nother study to be an earlier marker than serum creatinine
o reflect acute renal dysfunction.27 Additionally, a recent
tudy showed that NAC only had an effect on creatinine
evels in radiocontrast agent–induced nephropathy, without
ny effect on cystatin C levels.28 We therefore used both
reatinine and cystatin C as our renal function markers.
The time courses of these two markers were similar,
onsistent with the typical changes observed in clinical
ettings. Both injury markers, as well as the histologic
ndings, were attenuated dose dependently by the adminis-
ration of NAC. These protective effects occurred mainly
ecause of the relatively large doses we used in our exper-
ment. In most previous studies, the widely used dose was
00 mg/kg into the prime, followed by infusion at 20
g/(kg · h) or less.2,10-15 Because NAC is inexpensive, safe,
nd well tolerated, we used higher dose in this study and
ound a renal protective effect. We also used a dose of 1000
g/kg in our preliminary experiment, but this caused he-
odynamic instability.
A dose-dependent diuretic effect of NAC was also seen
n this study. This is probably because of the high osmotic
ressure and vasodilatation effect of the 20% NAC solution
e used; it may also be one of the manifestations of pro-
ected renal function. Diuretics, such as mannitol and furo-
emide, can also significantly increase urinary volume and
educe tubular obstruction; however, recent studies con-
erning their renal protective effects have had inconsistent
uced glutathione, superoxide dismutase, and catalase
utathione
protein)
Superoxide dismutase
(U/mg protein)
Catalase
(katals/g protein)
0.98 95.18 8.14 8.04 0.60
1.90* 38.52 2.81* 6.22 0.65*
1.74* 53.48 3.82*‡ 6.91 0.39†
1.56‡§ 87.22 8.25‡§ 8.01 0.51‡2
.05 for difference from sham group. ‡P  .01 for difference from control
difference from low–N-acetylcysteine group.red
ed gl
l/mg
39
09
80
22
†P esults.3 Mannitol prevented acute renal failure only in
and Cardiovascular Surgery ● Volume 133, Number 3 701
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CSPhabdomyolysis and kidney transplant surgery, whereas
oop diuretics were associated with a higher risk of delayed
ecovery of renal function.29 Furthermore, in our study
AC decreased serum creatinine and cystatin C and im-
roved renal histologic condition rather than merely in-
reasing urinary volume.
Our results demonstrate that oxidative stress induced
eduction of antioxidants and elevation of MDA in renal
issue. These data are in good agreement with the work of
ther researchers.6 Our biochemical results demonstrated
hat antioxidant therapy with NAC prevented lipid peroxi-
ation and caused increased activity of SOD and catalase in
enal tissue after CPB, as well as a significant elevation of
SH level.
Because of its principal role in initiating the cascade of
ctivation of other cytokines in the inflammatory response,
NF- is regarded as the most important proinflammatory
ytokine. NF-B is considered one of the most important
ranscription factors modulating its gene expression.
AC treatment significantly inhibited the CPB-induced
nflammation response and reduced the tissue expression
f NF- B, which confirms other research.23,30
Apart from its antioxidative and anti-inflammatory char-
cteristics, NAC may protect renal function through other
echanisms. Lessio and associates31 found that NAC blunts
he reduction of inducible nitric oxide synthase expression
nd nitric oxide synthesis caused by cyclosporine (INN
iclosporin) in rat renal artery vascular smooth muscle
ulture cells.31 Nitric oxide–independent vasodilation with
AC has also been reported.4
Despite our encouraging findings, there were several
imitations of this experiment. We only gave a bolus dose of
AC into the prime and only observed the renal function for
2 hours after the operation. Further long-term studies
hould be performed to investigate the protective effects of
AC in CPB models.
onclusions
ur experiment demonstrated acute renal damage in a rat
odel of CPB, which was shown in both biochemical
arkers and morphologic examinations. NAC dose depen-
ently ameliorated the CPB-induced kidney injury, proba-
ly through its antioxidative and anti-inflammatory proper-
ies. Further clinical trials with higher doses of NAC should
e performed in patients undergoing CPB to evaluate its
enal effects.
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